Endocrinopathy risk highlighted among childhood brain tumour survivors
Around 70% of children who survive a brain tumour develop at least one form of endocrine dysfunction, suggests a long-term study of patients attending a hospital in Portugal.
Around 70% of children who survive a brain tumour develop at least one form of endocrine dysfunction, suggests a long-term study of patients attending a hospital in Portugal.
Children with congenital adrenal hyperplasia have an increased propensity to develop cardiometabolic risk factors in childhood, research shows.
Researchers report that good outcomes are possible for children with autosomal recessive pseudohypoaldosteronism type 1, despite its high morbidity and mortality risk.
Faster diagnosis and use of individualised treatments for congenital hyperinsulinism has led to major improvements in neurological and endocrine outcomes over time, say Finnish researchers.
Longitudinal study findings support a relationship between body mass index and the timing of puberty in boys, with a link found between obesity and precocious gonadarche.
Collagenopathies could account for around one in 10 cases of familial short stature even when there are no obvious signs of dysplasia, say researchers.
A 6 years and 5-month-old girl with Prader-Willi Syndrome (PWS) attends endocrine clinic with her mother. She was first seen by the endocrine team at 18 months old and the referral was made by a geneticist. Mum reports she has been obsessive and extremely challenging with her behaviour around food, and she is concerned about her child’s weight.
Researchers have detected a global increase in the incidence of thyroid cancer among children and adolescents similar to that reported for the adult population, raising concerns that screening-related overdiagnosis may also be occurring in young people.
A study of children with Noonan syndrome treated in clinical practice shows a good response to growth hormone treatment, with the majority achieving a height within population norms.
A systematic review and meta-analysis suggests that girls with idiopathic central precious puberty who are treated with gonadotropin-releasing hormone analogue therapy may expect to have a higher final adult height and lower BMI than if they do not receive the treatment.